scholarly journals Differentiation of human germ cell tumor cells in vivo and in vitro.

1992 ◽  
Vol 25 (5) ◽  
pp. 563-576 ◽  
Author(s):  
JUN-ICHI HATA ◽  
JUNICHIRO FUJIMOTO ◽  
EIZABURO ISHII ◽  
AKIHIRO UMEZAWA ◽  
YASUO KOKAI ◽  
...  
2020 ◽  
Vol 489 ◽  
pp. 79-86
Author(s):  
Takeshi Namekawa ◽  
Sachi Kitayama ◽  
Kazuhiro Ikeda ◽  
Kuniko Horie-Inoue ◽  
Takashi Suzuki ◽  
...  

APOPTOSIS ◽  
2013 ◽  
Vol 18 (4) ◽  
pp. 480-491 ◽  
Author(s):  
V. Mauro ◽  
D. Carette ◽  
R. Pontier-Bres ◽  
J. Dompierre ◽  
D. Czerucka ◽  
...  

Cells ◽  
2019 ◽  
Vol 8 (12) ◽  
pp. 1637 ◽  
Author(s):  
João Lobo ◽  
Ad J.M. Gillis ◽  
Annette van den Berg ◽  
Lambert C.J. Dorssers ◽  
Gafanzer Belge ◽  
...  

Liquid biopsy-based biomarkers, such as microRNAs, represent valuable tools for patient management, but often do not make it to integration in the clinic. We aim to explore issues impeding this transition, in the setting of germ cell tumors, for which novel biomarkers are needed. We describe a model for identifying and validating clinically relevant microRNAs for germ cell tumor patients, using both in vitro, in vivo (mouse model) and patient-derived data. Initial wide screening of candidate microRNAs is performed, followed by targeted profiling of potentially relevant biomarkers. We demonstrate the relevance of appropriate (negative) controls, experimental conditions (proliferation), and issues related to sample origin (serum, plasma, cerebral spinal fluid) and pre-analytical variables (hemolysis, contaminants, temperature), all of which could interfere with liquid biopsy-based studies and their conclusions. Finally, we show the value of our identification model in a specific scenario, contradicting the presumed role of miR-375 as marker of teratoma histology in liquid biopsy setting. Our findings indicate other putative microRNAs (miR-885-5p, miR-448 and miR-197-3p) fulfilling this clinical need. The identification model is informative to identify the best candidate microRNAs to pursue in a clinical setting.


2001 ◽  
Vol 19 (12) ◽  
pp. 3029-3036 ◽  
Author(s):  
C. Bokemeyer ◽  
A. J.M. Gillis ◽  
K. Pompe ◽  
F. Mayer ◽  
B. Metzner ◽  
...  

PURPOSE: High-dose chemotherapy (HD-Ctx) followed by autologous peripheral-blood stem-cell (PBSC) transplantation is currently investigated in patients with poor prognosis or relapsed metastatic germ cell tumor (GCTs). This study analyzed the presence and the clinical importance of contaminating tumor cells in PBSC preparations used to support HD-Ctx in GCT patients. PATIENTS AND METHODS: Seven targets for reverse transcription polymerase chain reaction (RT-PCR)-based detection of GCT cells were able to detect seminomatous and different histologic variants of nonseminomatous tumor cells. PBSC preparations from 57 patients were investigated for the presence of contaminating tumor cells using this set of targets, including beta human chorionic gonadotropin (β-hCG), fibronectin (EDB variant), epidermal growth factor receptor (EGFR), CD44 (v8 to 10 variant), germ cell and placental alkaline phosphatase (AP), human endogenous retrovirus type K (ENV and GAG), and XIST. Samples of PBSC preparations from four healthy donors for allogenic transplantations as well as blood specimens from 10 healthy volunteers served as negative controls. RESULTS: Fifty patients (43 first-line and seven second-line Ctx) were assessable. Combining all RT-PCR results, 29 PBSC preparations (58%) were positive for tumor-specific amplification products (HERV-K 0, fibronectin 4, XIST 14, β-hCG 19, AP 19, CD44 24, EGFR 26). Ten (35%) of 29 patients who underwent transplantation with positive PBSC preparations and seven (33%) of 21 patients with negative PBSC preparations have suffered relapse or progression (not significant [ns]). With a median follow-up of 22 months (2 to 66) post–HD-Ctx projected 3-year survival rates are 68% (RT-PCR+) and 58% (RT-PCR−) (ns). None of the 10 control peripheral-blood samples showed positivity for any of the targets studied. CONCLUSION: GCT cells can be detected in more than 50% of PBSC preparations using a RT-PCR approach with multiple targets. Despite the presence of tumor cells, retransplantation of the PBSC products did not effect long-term outcome. Factors such as responsiveness to chemotherapy and tumor mass seem to overcome the importance of potentially re-infused tumor cells.


1999 ◽  
Vol 249 (2) ◽  
pp. 199-211 ◽  
Author(s):  
Roger B. Voyle ◽  
Bryan P. Haines ◽  
Martin F. Pera ◽  
Regan Forrest ◽  
Peter D. Rathjen

Sign in / Sign up

Export Citation Format

Share Document